Packages (Simulation)
Image (II)
-
Figure. Western Blot; Sample: Recombinant FGF23, Human.
Quality Guarantee
Instruction Manual
Certificate
Monoclonal Antibody to Fibroblast Growth Factor 23 (FGF23)
ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
- Product No.MAA746Hu22
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- SourceMonoclonal antibody preparation
- HostMouse
- Potency (Clone Number)1-2#
- Ig Isotype IgG2a Kappa
- PurificationProtein A + Protein G affinity chromatography
- LabelNone
- Immunogen RPA746Hu01-Recombinant Fibroblast Growth Factor 23 (FGF23)
- Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
- TraitsLiquid
- Concentration0.79mg/mL
- Organism Species Moren/a
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies. - DownloadInstruction Manual
- UOM 20µl100µl 200µl 1ml 10ml
- FOB
US$ 101
US$ 235
US$ 336
US$ 840
US$ 3360
For more details, please contact local distributors!
SPECIFITY
The antibody is a mouse monoclonal antibody raised against FGF23. It has been selected for its ability to recognize FGF23 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
-
Antibody Labeling Customized Service
-
Protein A/G Purification Column
-
Staining Solution for Cells and Tissue
-
Positive Control for Antibody
-
Tissue/Sections Customized Service
-
Phosphorylated Antibody Customized Service
-
Western Blot (WB) Experiment Service
-
Immunohistochemistry (IHC) Experiment Service
-
Immunocytochemistry (ICC) Experiment Service
-
Flow Cytometry (FCM) Experiment Service
-
Immunoprecipitation (IP) Experiment Service
-
Immunofluorescence (IF) Experiment Service
-
Buffer
-
DAB Chromogen Kit
-
SABC Kit
-
Long-arm Biotin Labeling Kit
-
Real Time PCR Experimental Service
| Magazine | Citations |
| Journal of international medicine | Prognostic impact of renal function in precapillary pulmonary hypertension Pubmed: 24011362 |
| BMC Nephrology | FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients Pubmed: 24180481 |
| Journal of Clinical Densitometry | Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism Pubmed: 23623649 |
| J Intern Med. | Prognostic impact of renal function in precapillary pulmonary hypertension. Pubmed:24011362 |
| Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth Pubmed:25639729 |
| Nefrologia | Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina PubMed: 26394828 |
| Medicine (Baltimore) | An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer PubMed: 26266370 |
| Ann Biol Clin (Paris) | Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique? PubMed: 26069069 |
| Scandinavian Journal of Gastroenterology | High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23 Pubmed:27326766 |
| PLOS ONE | Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model ofDistal Nephron Salt Wasting. pubmed:27442254 |
| Journal of Laboratory Diagnostics | Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation publication:312592751 |
| Journal of Integrative Nephrology & Andrology | Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients issn:2394-2916 |
| Journal of Renal Nutrition | ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder. pubmed:29056164 |
| Experimental Biology and Medicine(Maywood) | Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats Pubmed:29763365 |
| Psychiatry Research | Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity Pubmed:29677623 |
| BMC Pediatrics | Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children Pubmed:29907141 |
| Medical Science Monitor | Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study Pubmed:29608553 |
| International Journal of Chronic Obstructive Pulmonary Disease | Disconnection of pulmonary and systemic arterial stiffness in COPD Pubmed:29881265 |
| Saudi journal of kidney diseases and transplantation | Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients Pubmed:29970732 |
| Nephrology Dialysis Transplantation | High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease Pubmed: 30189026 |
| BioFactors | Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma Pubmed: 30334297 |
| Biological Trace Element Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients Pubmed: 30847765 |
| Clin Implant Dent Relat Res. | Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases Pubmed: 31407857 |
| JACC-Cardiovascular Imaging | PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS Pubmed: 28797410 |
| Saudi J Kidney Dis Transpl | Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease Pubmed: 31696838 |
| Biomedicine & Pharmacotherapy | MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7 Pubmed: 31918268 |
| Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis? | |
| THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS | |
| THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ¡ | |
| Calcif Tissue Int | The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations Pubmed:35665817 |
| European Journal of Medical Genetics | Genetic and clinical profile of patients with hypophosphatemic rickets Pubmed:35738466 |
| African Health Sciences | Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease |